Veozah (fezolinetant) — United Healthcare
moderate to severe vasomotor symptoms due to menopause
Preferred products
- hormonal therapy (e.g., estradiol, Premarin, Prempro)
- non-hormonal therapy [e.g., clonidine, gabapentin, selective serotonin inhibitors (e.g., paroxetine), serotonin and norepinephrine reuptake inhibitors (e.g., venlafaxine)]
Initial criteria
- Diagnosis of moderate to severe vasomotor symptoms due to menopause
- AND History of failure (after a 30-day trial), contraindication or intolerance to one of the following: hormonal therapy (e.g., estradiol, Premarin, Prempro) OR non-hormonal therapy [e.g., clonidine, gabapentin, selective serotonin inhibitors (e.g., paroxetine), serotonin and norepinephrine reuptake inhibitors (e.g., venlafaxine)]
- AND Patient has received baseline hepatic laboratory tests to rule out the presence of underlying liver disease
Reauthorization criteria
- Documentation of positive clinical response to therapy (e.g., decrease in frequency and severity of vasomotor symptoms from baseline)
- AND Patient has received periodic evaluation of hepatic laboratory tests to rule out liver injury associated with Veozah use
Approval duration
12 months